Location:Room 1 (ICM, Level 0)
Early detection and treatment can decrease the mortality of prostate cancer, but only at the cost of the diagnosis of harmless tumours. This session will inform the urologist about the methods used to distinguish between low and higher risk cancers, and the management of men with indolent disease.
– The audience will know the arguments in favour and against population based screening
– The audience will be able to give a definition of low risk cancer together with risk factors for more aggressive disease
– The audience will know how to perform active surveillance, and when to switch to invasive therapy. Developments in technology to treat these intermediate risks with the least possible side effects will be discussed.
The objective is to review all the evidence on screening for prostate cancer. The talk will highlight the pros and cons of establishing a population-based early detection programme versus individualised and targeted screening and the way forward.
Patients with Gleason score 6 prostate cancer on radical prostatectomy have excellent outcome. The objectives of this presentation are 1) to investigate whether Gleason score 6 tumors should still be considered cancer, and 2) to determine whether Gleason score 7 subpopulations with very good prognosis can be identified. Urologists will learn how recent developments in pathology can support their therapeutic decisions for individual prostate cancer patients.
1. To review current selection criteria for active surveillance
2. To review recent data on parameters predicting for risk of metastatic progression in men on surveillance
3. To review the role of MRI and biomarkers in patients selection and intervention
Show the possibilities of focal radiotherapy for primary and salvage prostate cancer treatments
Institutes: 1Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, 2Karolinska Institutet, Dept. of Clinical Science, Intervention and Technology (CLINTEC), Stockholm, Sweden, 3Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, 4Karolinska Institutet, Dept. of Oncology-Pathology, Stockholm, Sweden, 5Karolinska Institutet, Biobank, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden